secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001607678-25-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial
----------------------------------------------------------------------------

- Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).
- Up to 97% of VK2735 subjects achieved ≥5% weight loss vs 10% placebo; up to 80% achieved ≥10% vs 5% placebo.
- Safety: 99% of GI-related TEAEs mild/moderate; discontinuation due to AE in 20% VK2735 vs 13% placebo.
- Statistically significant weight loss seen in all doses >15 mg from Week 1 through Week 13.
- Exploratory maintenance arm: weight loss sustained after down-titration from 90 mg to 30 mg daily for 7 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/0001607678-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/vktx-20250819.htm
  HTML page:      https://secwatch.observer/filing/0001607678-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer